Stock BRNS BARINTHUS BIOTHERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Barinthus Biotherapeutics plc

Equities

BRNS

US91864C1071

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.5 USD +2.93% Intraday chart for Barinthus Biotherapeutics plc -0.40% -32.25%
Apr. 18 Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours MT
Apr. 18 BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections CI

Evolution of the average Target Price on Barinthus Biotherapeutics plc

Price target over the last 5 years

History of analyst recommendation changes

f34ded08e7.ySZT57KUTd82ySYNNs-RvNZikqUsx3YwTFO-xH7UIDg.nEc3lfz7KLF-uEp9Zq789J9TxvZZ9zRUPGP9rTu6RQ-rZDqy8fkAnm-YHg~e23115c0654f63389536561e31ea69e8

Analyst Recommendations on Barinthus Biotherapeutics plc

Vaccitech Shares Rise After Alliance Global Partners Begins Coverage With Buy Rating MT
Alliance Global Partners Initiates Coverage on Vaccitech with Buy Rating, $12 Price Target MT
Morgan Stanley Downgrades Vaccitech to Equal Weight From Overweight, Cuts Price Target to $3.25 From $14 MT
Morgan Stanley Adjusts Price Target on Vaccitech to $14 From $15, Maintains Overweight Rating MT
Morgan Stanley Adjusts Price Target on Vaccitech to $15 From $16, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Vaccitech to $15 From $20, Maintains Buy Rating MT
Possibility of US Fed's Rate Hike Pause Supports American Depositary Receipts of European Equities MT
Morgan Stanley Adjusts Price Target on Vaccitech to $16 From $19, Maintains Overweight Rating MT
HC Wainwright Adjusts Vaccitech's Price Target to $20 From $22, Keeps Buy Rating MT
Morgan Stanley Trims Vaccitech's Price Target to $19 From $20, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Vaccitech to $23 From $25, Maintains Buy Rating MT
VACCITECH : Barclays Initiates Coverage on Vaccitech With Overweight Rating, $23 Price Target MT
VACCITECH : William Blair Initiates Coverage on Vaccitech With Outperform Rating MT
VACCITECH : Morgan Stanley Starts Vaccitech at Overweight With $22 Price Target MT
VACCITECH : Jefferies Starts Vaccitech at Buy With $28 Price Target MT
VACCITECH : HC Wainwright Starts Vaccitech at Buy With $25 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.5 USD
Average target price
7.4 USD
Spread / Average Target
+196.00%
High Price Target
12 USD
Spread / Highest target
+380.00%
Low Price Target
3 USD
Spread / Lowest Target
+20.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Barinthus Biotherapeutics plc

Alliance Global Partners
Morgan Stanley
HC Wainwright
Jefferies & Co.
William Blair & Co.
Barclays

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BRNS Stock
  4. Consensus Barinthus Biotherapeutics plc